Physician profile
Cheryl Ann Mann
NPI 1265437354
$765.48
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $336 · 2020: $87.24 · 2021: $271 · 2022: $71.54.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $163.22 | 2019-2021 | |
| Amgen INC. | $59.73 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.61 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $54.52 | 2019-2021 | |
| Abbvie INC. | $50.55 | 2021 | |
| Zyla Life Sciences, INC. | $48.36 | 2019-2020 | |
| Pfizer INC. | $47.78 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $41.85 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $40.45 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.92 | 2021 | |
| Lilly USA, LLC | $28.86 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $25.89 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $24.29 | 2019 | |
| Abbott Laboratories | $19.86 | 2021 | |
| Glaxosmithkline, LLC. | $17.54 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $15.38 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.74 | 2021 | |
| Astellas Pharma US INC | $12.65 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $12.28 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cheryl Mann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.